Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.
Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi...
Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF)...
Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 ...
Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical...
Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from...
Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received...
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. ...
Palm Beach, FL – September 17, 2021 – FinancialNewsMedia.com News Commentary – The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer...
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...